Advertisement

Topics

Merck's advanced liver cancer therapy accepted for priority review

05:50 EDT 12 Jul 2018 | SmartBrief

Merck's Keytruda, or pembrolizumab, being developed as a treatment for patients with advanced hepatocellular carcinoma, was a -More

Original Article: Merck's advanced liver cancer therapy accepted for priority review

NEXT ARTICLE

More From BioPortfolio on "Merck's advanced liver cancer therapy accepted for priority review"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...